Entrada Therapeutics (TRDA) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Entrada Therapeutics (NASDAQ: TRDA) recently:

• 10/24/2026 – Entrada Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/19/2026 – Entrada Therapeutics had its “neutral” rating reaffirmed by UBS Group.
• 10/19/2026 – Entrada Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 10/16/2026 – Entrada Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/2/2026 – Entrada Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/26/2026 – Entrada Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/16/2026 – Entrada Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/5/2026 – Entrada Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/31/2026 – Entrada Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the transaction, the insider directly owned 3,885,115 shares of the company’s stock, valued at $27,700,869.95. The trade was a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the transaction, the insider owned 4,318,348 shares in the company, valued at approximately $30,487,536.88. This represents a 0.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 717,449 shares of company stock worth $5,134,773. 9.49% of the stock is owned by company insiders.

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.